FLT3-CD28-CD3zeta CAR T cells

FLT3-CD28-CD3zeta CAR T cells are an investigational second-generation chimeric antigen receptor (CAR) T-cell therapy designed to target FMS-like tyrosine kinase 3 (FLT3), a cell surface receptor frequently overexpressed in acute myeloid leukemia (AML). The CAR construct features an extracellular binding domain specific for FLT3, linked to intracellular signaling components including the CD28 costimulatory domain and the CD3zeta activation domain. This configuration is intended to provide both the primary activation signal and a secondary costimulatory signal upon antigen binding, which enhances T-cell proliferation, metabolic fitness, and persistence. Preclinical studies have demonstrated that these CAR T cells maintain superior cytotoxic capacity and resistance to exhaustion compared to bispecific T-cell engagers (BiTEs) during prolonged antigen exposure, effectively controlling tumor growth in AML xenograft models while sparing healthy hematopoietic stem and progenitor cells.

Other names

FLT3-directed CAR T cellsFLT-3-directed CAR T cellsFLT 3-directed CAR T cellsFLT3-specific CAR T cellsFLT-3-specific CAR T cellsFLT 3-specific CAR T cellsFLT3-CD28-zeta CAR T cellsFLT-3-CD28-zeta CAR T cellsFLT 3-CD28-zeta CAR T cellssecond-generation FLT3-specific CAR T cells